Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
0.9909
-0.0091 (-0.91%)
Nov 18, 2026, 4:00 PM EST - Market closed
Geron Revenue
Geron had revenue of $60.19M in the quarter ending September 30, 2026, with 27.45% growth. This brings the company's total for the last twelve months to $217.52M, up 18.60% year-over-year. In the year 2025, Geron had annual revenue of $183.88M with 138.83% growth. That makes Geron the 16,933rd largest company in the world by revenue and 2,824th in the United States.
Revenue (ttm)
$217.52M
Revenue Growth
+18.60%
P/S Ratio
2.93
Revenue / Employee
$843,109
Employees
258
Market Cap
638.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 183.88M | 106.89M | 138.83% |
| Dec 31, 2024 | 76.99M | 76.76M | 32,386.92% |
| Dec 31, 2023 | 237.00K | -359.00K | -60.23% |
| Dec 31, 2022 | 596.00K | -797.00K | -57.21% |
| Dec 31, 2021 | 1.39M | 1.14M | 450.59% |
| Dec 31, 2020 | 253.00K | -207.00K | -45.00% |
| Dec 31, 2019 | 460.00K | -606.00K | -56.85% |
| Dec 31, 2018 | 1.07M | 1.00K | 0.09% |
| Dec 31, 2017 | 1.07M | -5.10M | -82.72% |
| Dec 31, 2016 | 6.16M | -30.21M | -83.06% |
| Dec 31, 2015 | 36.37M | 35.22M | 3,054.47% |
| Dec 31, 2014 | 1.15M | -130.00K | -10.13% |
| Dec 31, 2013 | 1.28M | -1.43M | -52.64% |
| Dec 31, 2012 | 2.71M | 271.00K | 11.12% |
| Dec 31, 2011 | 2.44M | -1.13M | -31.57% |
| Dec 31, 2010 | 3.56M | 1.84M | 106.43% |
| Dec 31, 2009 | 1.73M | -1.08M | -38.42% |
| Dec 31, 2008 | 2.80M | -4.82M | -63.22% |
| Dec 31, 2007 | 7.62M | 4.35M | 132.59% |
| Dec 31, 2006 | 3.28M | -2.88M | -46.78% |
| Dec 31, 2005 | 6.16M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arbutus Biopharma | 181.49M |
| 4D Molecular Therapeutics | 96.06M |
| Crescent Biopharma | 15.00M |
| Surrozen | 10.53M |
| Aclaris Therapeutics | 6.40M |
GERN News
- 12 hours ago - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Geron Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 13 days ago - Geron price target lowered to $3.50 from $4 at Stifel - TheFly
- 14 days ago - Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 - GlobeNewsWire
- 14 days ago - Geron Earnings Call Transcript: Q3 2026 - Transcripts
- 14 days ago - Geron Earnings release: Q3 2026 - Filings
- 14 days ago - Geron Quarterly report: Q3 2026 - Filings
- 14 days ago - Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire